Metabolic Effects of Olanzapine in Healthy Males
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14215
- Department of Psychiatry, The State University of New York at Buffalo
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Volunteer
- Male
- Aged 18-35 years
- Body Mass Index (BMI): <30 kg/m2
Exclusion Criteria:
- Presence of any medical disorder that may confound the assessment of relevant biological measures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Placebo capsule administered orally at bedtime for 14 days
|
|
EXPERIMENTAL: Olanzapine
|
Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in Weight
Time Frame: Assessed at baseline and 2 weeks
|
Assessed at baseline and 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Body Composition
Time Frame: baseline and 2 weeks of treatment (olanzapine or placebo)
|
lean body mass (kg) and fat mass (kg) at baseline and after 2 weeks of treatment with olanzapine or placebo
|
baseline and 2 weeks of treatment (olanzapine or placebo)
|
|
Change From Baseline in 24-Hour Dietary Recall
Time Frame: Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
24-hour dietary intake recall at baseline and after 2 weeks of treatment with olanzapine or placebo
|
Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
|
Change From Baseline in Resting Metabolic Rate
Time Frame: baseline and 2weeks of treatment
|
Resting metabolic rate at baseline and after 2 weeks of treatment
|
baseline and 2weeks of treatment
|
|
Change From Baseline Triglycerides
Time Frame: Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
Triglycerides (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo
|
Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
|
Change From Baseline in Glucose
Time Frame: Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
Glucose (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo
|
Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
|
Change From Baseline in Leptin
Time Frame: Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
Leptin (ng/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo
|
Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
|
Change From Baseline in Insulin
Time Frame: Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
Insulin (µIU/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo
|
Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)
|
|
Change From Baseline Total Cholesterol
Time Frame: baseline and 2 weeks treatment
|
Total cholesterol at baseline and after 2 weeks treatment with olanzapine or placebo
|
baseline and 2 weeks treatment
|
|
LDL
Time Frame: baseline and 2 weeks treatment
|
Low-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo
|
baseline and 2 weeks treatment
|
|
HDL
Time Frame: baseline and 2 weeks treatment
|
High-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo
|
baseline and 2 weeks treatment
|
|
Physical Activity as Measured Using a Physical Activity Monitor
Time Frame: baseline and 2 week treatment
|
Change from baseline in physical activity.
Physical activity was measured using an activity monitor that subjects wore around their waist throughout baseline and treatment days.
Subjects were instructed to remove the monitor when sleeping or engaging in water-based activities, and to report on a daily log the times that they were wearing and removing the device.
Physical activity was monitored during weekdays and weekend days.
Physical activity data were collected in 60-second epochs.
The results are reported as average counts per day of physical activity for weekdays and weekend days at baseline and 2 week treatment.
|
baseline and 2 week treatment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Laboratory Breakfast Intake
Time Frame: baseline and 2 week treatment
|
Total kcal intake at breakfast in a laboratory setting at baseline and after 2 week of treatment with olanzapine or placebo
|
baseline and 2 week treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Steven L Dubovsky, M.D., The State University of New York at Buffalo
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Olanzapine
Other Study ID Numbers
Other Study ID Numbers
- PCH0320106A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.